Zacks: Analysts Anticipate Aerie Pharmaceuticals, Inc. (AERI) to Announce -$1.44 Earnings Per Share

Equities analysts forecast that Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) will post earnings of ($1.44) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Aerie Pharmaceuticals’ earnings. The highest EPS estimate is ($1.38) and the lowest is ($1.50). Aerie Pharmaceuticals reported earnings of ($0.72) per share during the same quarter last year, which would suggest a negative year over year growth rate of 100%. The firm is expected to issue its next earnings report on Tuesday, March 6th.

On average, analysts expect that Aerie Pharmaceuticals will report full-year earnings of ($3.42) per share for the current financial year, with EPS estimates ranging from ($3.49) to ($3.34). For the next fiscal year, analysts forecast that the business will report earnings of ($2.10) per share, with EPS estimates ranging from ($2.38) to ($1.82). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Aerie Pharmaceuticals.

A number of equities research analysts have recently issued reports on AERI shares. Zacks Investment Research upgraded Aerie Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $66.00 price target for the company in a research report on Monday, July 24th. BidaskClub upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, July 24th. Stifel Nicolaus restated a “buy” rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a research report on Friday, July 28th. Canaccord Genuity set a $65.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 1st. Finally, HC Wainwright set a $69.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company. Aerie Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $71.43.

A number of large investors have recently added to or reduced their stakes in AERI. BlackRock Inc. lifted its stake in Aerie Pharmaceuticals by 113,376.8% during the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock worth $117,951,000 after purchasing an additional 2,598,596 shares in the last quarter. Vanguard Group Inc. lifted its stake in Aerie Pharmaceuticals by 55.0% during the second quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock worth $113,446,000 after purchasing an additional 766,300 shares in the last quarter. Senzar Asset Management LLC acquired a new position in Aerie Pharmaceuticals during the second quarter worth $20,568,000. Broadfin Capital LLC acquired a new position in Aerie Pharmaceuticals during the second quarter worth $16,291,000. Finally, AXA acquired a new position in Aerie Pharmaceuticals during the second quarter worth $10,961,000. Institutional investors own 95.71% of the company’s stock.

Aerie Pharmaceuticals (NASDAQ:AERI) traded down $1.00 during mid-day trading on Wednesday, hitting $58.70. The stock had a trading volume of 378,123 shares, compared to its average volume of 638,111. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a 1-year low of $35.20 and a 1-year high of $66.25.

WARNING: “Zacks: Analysts Anticipate Aerie Pharmaceuticals, Inc. (AERI) to Announce -$1.44 Earnings Per Share” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/11/18/zacks-analysts-anticipate-aerie-pharmaceuticals-inc-aeri-to-announce-1-44-earnings-per-share.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply